« ISM Manufacturing On Tap
MCG Capital gets $70 million credit line »

Acorda Therapeutics’ MS drug trial shows ‘positive’ results

WASHINGTON (MarketWatch) — Acorda Therapeutics Inc. said a second Phase III clinical trial of Fampridine-SR on the walking ability of people who suffer from multiple sclerosis has yielded “positive” results. Consistent improvement in walking speed was the primary endpoint of the study. A “significantly greater proportion” of trial participants taking Fampridine-SR showed such improvement compared to people taking a placebo, reflecting better leg strength, according to Hawthorne, N.Y.-based Acorda. Dr. Ron Cohen, president and CEO, said Acorda expects to submit a new drug application in the first quarter of 2009 and plans to request priority review by the Food and Drug Administration. (Refiled to fix spelling of company name.)

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Original post by Forextvblog

This entry was posted on Monday, June 2nd, 2008 at 3:15 am and is filed under Daily Forex Analysis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply